Tempest Therapeutics TPST

Tempest is a clinical stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. The company focuses on developing treatments for hematologic malignancies solid tumors and immunology indications. Its pipeline includes dual targeting chimeric antigen receptor T cell therapies and oral small molecule antagonists aimed at high unmet medical needs. Tempest aims to bring first in class therapies to patients by leveraging scientific insight and strategic partnerships. The firm operates with a lean team and relies on external expertise to move candidates through preclinical and clinical stages.

Tempest generates revenue primarily through collaboration agreements licensing arrangements and grant funding. The company has partnered with Roche for the clinical development of its small molecule candidate amezalpat and receives support from the National Cancer Institute for its second small molecule program. These collaborations provide financial resources and reduce internal costs while advancing product candidates toward potential commercialization. In addition Tempest may earn milestone payments and royalties from successful partnerships. The business model emphasizes capital efficiency and seeks to limit cash burn while progressing multiple programs.

The company operates through the following segments. These segments reflect distinct therapeutic modalities and allow focused resource allocation.

• CAR T Cell Therapy Programs: This segment develops autologous and allogeneic dual targeting chimeric antigen receptor T cell therapies for multiple myeloma solid tumors and lupus. Programs include TPST 2003 targeting CD19 and BCMA TPST 2206 targeting CD70 and the allogeneic counterparts TPST 3003 and TPST 3206 as well as an in vivo approach TPST 4003. The segment leverages a shared dual targeting architecture designed to improve tumor coverage and reduce antigen escape. Manufacturing strategies vary from patient derived autologous processes to off the shelf allogeneic platforms.

• Small Molecule Programs: This segment advances oral small molecule inhibitors of metabolic and inflammatory pathways. The lead candidate amezalpat acts as a peroxisome proliferator activated receptor alpha antagonist for hepatocellular carcinoma while the second candidate TPST 1495 dual antagonizes EP2 and EP4 prostaglandin receptors for familial adenomatous polyposis. Both molecules are being evaluated in clinical trials with the goal of demonstrating disease modifying activity. The segment pursues partnership opportunities to fund later stage studies and potential registration.

Within the competitive biotechnology landscape Tempest occupies a niche as a developer of first in class dual targeting cell therapies and novel small molecule mechanisms. Its advantages include a dual targeting CAR design that may reduce antigen escape and partnerships that provide non dilutive funding. The company also benefits from a focused pipeline that concentrates on high unmet needs in oncology and immunology. Competitors include large pharmaceutical firms such as Johnson & Johnson Bristol Myers Squibb Gilead Sciences and specialized biotechs like Legend Biotech Arcellyx and Allogene that pursue similar CAR T and small molecule approaches.

Tempest serves patients with hematologic malignancies solid tumors and immunologic disorders. Its customers are expected to be hospitals specialty clinics and healthcare providers that administer its therapies once approved. The company also considers payers and prescription benefit managers as important stakeholders in the commercialization process. Specific customer names are not disclosed at this stage of development.